Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mepolizumab adjunctive therapy in severe uncontrolled refractory asthma
2012-001251-40Phase 3Completed
- Sponsor
- GSK
- Start
- Jul 2012
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of mepolizumab in asthma and eosinophilic asthma (EA) (3 arms), sponsored by GSK. Primary endpoint: Frequency of clinically significant exacerbations of asthma. Started Jul 2012; status: completed.
02
Drugs
mepolizumab
03
Conditions
asthmaeosinophilic asthma (EA)
Beyond the preview
Go deeper on 2012-001251-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-001251-40.